Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg once-weekly in obesity-related HFpEF with type 2 diabetes
2020-004170-22Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), type 2 diabetes mellitus (T2DM) and obesity comparing Semaglutide 2.4 mg once-weekly + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in KCCQ clinical summary score. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2020-004170-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004170-22.